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Phosphate binder therapy for attainment of K/DOQITM bone
metabolism guidelines. Hyperphosphatemia in patients with
chronic kidney disease leads to secondary hyperparathyroidism
and renal osteodystrophy, and it is independently associated
with mortality risk. The exact mechanism by which hyper-
phosphatemia increases mortality risk is unknown, but it may
relate to enhanced cardiovascular calcification. The National
Kidney Foundation Kidney Disease Outcomes Quality Ini-
tiative (K/DOQITM) Clinical Practice Guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease recom-
mends maintenance of serum phosphorus below 5.5 mg/dL,
calcium-phosphorus (Ca × P) product less than 55 mg2/dL2, in-
tact parathyroid hormone (iPTH) 150 pg/mL to 300 pg/mL, and
bicarbonate (HCO3) greater than 22 mEq/L. Although calcium-
based phosphate binders (CBPB) are cost effective, there are
long-term safety concerns pertaining to their postulated role in
the progression of cardiovascular calcification. Sevelamer hy-
drochloride has been recommended as an alternative noncal-
cium phosphate binder. Results from the Calcium Acetate Re-
nagel Evaluation (CARE) study indicate that calcium acetate
is more effective than sevelamer hydrochloride in controlling
serum phosphorous, Ca × P product, and HCO3 in hemodialy-
sis patients. In the Treat-to-Goal study, dialysis patients treated
with sevelamer hydrochloride had slower progression of coro-
nary and aortic calcification than patients treated with CBPB.
The mechanism underlying the beneficial effect of sevelamer
hydrochloride is unknown but may relate to decreased calcium
loading, or to dramatic reductions in low-density lipoprotein
(LDL) cholesterol in sevelamer hydrochloride-treated patients.
At present, evidence incriminating CBPB in the progression of
cardiovascular calcification in end-stage renal disease (ESRD)
remains largely circumstantial. As calcium acetate is more effi-
cacious and cost effective than sevelamer hydrochloride, it re-
mains an accepted first-line phosphate binder. This review ex-
amines these issues and provides rational guidelines for the use
of CBPB in patients on maintenance hemodialysis.
The treatment of hyperphosphatemia in patients with
chronic kidney disease (CKD) remains a vexing clinical
problem. Hyperphosphatemia not only underlies the de-
velopment of secondary hyperparathyroidism and renal
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osteodystrophy, but it is also independently associated
with an increased risk of death among dialysis patients [1,
2]. Although dietary phosphorus restriction to less than
800 mg/day while maintaining adequate protein intake of
1 g/kg/day is the first line of treatment, patient persistence
with dietary therapy is often problematic. Furthermore,
intermittent hemodialysis as currently performed 3 times
weekly is usually inadequate to maintain normal phos-
phorus balance. Guidelines issued by the National Kid-
ney Foundation K/DOQI TM [3] provide recommended
target ranges for serum phosphorus, serum calcium, Ca
× P product, intact parathyroid hormone (iPTH) levels,
and serum HCO3 for patients with CKD receiving main-
tenance dialysis (Table 1). Large cross-sectional studies
have indicated that a substantial percentage of dialysis pa-
tients fail to achieve the K/DOQITM guidelines for serum
phosphorus and Ca × P product, despite treatment with
dietary phosphorus restriction, conventional hemodialy-
sis, and phosphate binders [1, 2].
PATHOPHYSIOLOGY OF SECONDARY
HYPERPARATHYROIDISM
In the setting of CKD, secondary hyperparathyroidism
develops as a consequence of phosphate retention and
the reduced renal production of active vitamin D, result-
ing in hyperphosphatemia, hypocalcemia, and increased
PTH levels. Over the long term, the same factors cause
parathyroid gland hyperplasia and autonomous PTH pro-
duction (tertiary hyperparathyroidism) [4, 5]. A chronic
decrease in serum calcium and 1,25-dihydroxyvitamin D
levels, or an increase in serum phosphorous, leads to
a secondary increase in serum PTH as a result of in-
creases in PTH gene expression, synthesis, and secre-
tion, and the eventual proliferation of parathyroid chief
cells with gland hyperplasia. Low serum calcium leads to
an increase in PTH secretion, an increase in PTH mes-
senger RNA stability, and parathyroid cell proliferation.
Chronic increases in serum phosphorous also regulate
PTH secretion in a similar manner. The effects of cal-
cium on parathyroid cells are mediated by a membrane-
bound calcium-sensing receptor. The pathophysiologic
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Table 1. NKF K/DOQITM recommended target rangesa
Laboratory parameter Treatment goal
Serum phosphorus 3.5 mg/dL–5.5 mg/dL
Serum calcium 8.4 mg/dL–9.5 mg/dL
Ca × P product <55 mg2/dL2
Intact PTH 150 pg/mL–300 pg/mL
Serum total CO2 >22 mmol/L
Abbreviations are: CO2, carbon dioxide; NKF K/DOQITM, National Kidney
Foundation Kidney Disease Outcomes Quality Initiative; Ca × P product,
calcium-phosphorus product; PTH, parathyroid hormone. Reprinted with
permission from Elsevier Science.
mechanisms summarized in Figure 1 that underlie the de-
velopment of hyperphosphatemia and secondary hyper-
parathyroidism in CKD provide the clinical rationale for
treatment strategies that include maintenance of normal
serum phosphorus levels (dietary phosphorus restriction,
dietary phosphate binders, and short daily hemodialysis),
maintenance of normal serum calcium (reduced dialysate
calcium levels and judicious use of vitamin D analogues),
and suppression of PTH secretion (phosphorus control,
maintenance of normocalcemia, and treatment with vi-
tamin D analogues and/or calcimimetic agents such as
cinacalcet).
THE CALCIUM ACETATE RENAGEL
EVALUATION STUDY
Large cross-sectional studies have found a mean serum
phosphorus level of 6.2 mg/dL in the maintenance
hemodialysis population in the United States [1]. More-
over, an alarming 60% of patients had serum phos-
phorus levels in excess of the 5.5-mg/dL target level
recommended by K/DOQITM guidelines. Although
aluminum-containing phosphate binders are efficacious,
the long-term use of these compounds has been largely
abandoned because of the risk of aluminum accumula-
tion leading to osteomalacia and encephalopathy. As a
result, CBPB such as calcium acetate and calcium car-
bonate have replaced aluminum hydroxide as the most
widely prescribed phosphate binders. However, recent
concern over the possible risks of calcium loading from
these binders has led to the introduction of the consid-
erably more expensive noncalcium, nonaluminum phos-
phate binder sevelamer hydrochloride (Renagel) [6, 7].
At present in clinical practice, calcium acetate and seve-
lamer hydrochloride are the 2 most commonly prescribed
phosphate binders in the United States. The recently pub-
lished CARE study was the first prospective, randomized,
double-blind, multicenter study comparing the efficacy
and safety of calcium acetate and sevelamer hydrochlo-
ride for the treatment of hyperphosphatemia in patients
with CKD on maintenance hemodialysis [8]. The primary
end points of the study were to determine whether cal-
cium acetate or sevelamer hydrochloride best achieved
recently recommended treatment goals for serum phos-
phorus (<5.5 mg/dL) and Ca × P product (<55 mg2/dL2).
The baseline characteristics of the patients receiving cal-
cium acetate (N = 48) or sevelamer hydrochloride (N =
50) were similar with respect to age, sex, race, years on
dialysis, and vitamin D therapy. In addition, patients in
both groups had similar baseline values for serum phos-
phorus, serum calcium, Ca × P product, iPTH, and serum
HCO3. At all time points in the 8-week study, the serum
phosphorus concentration (Fig. 2) and the Ca × P product
(Fig. 3) were significantly lower in patients receiving cal-
cium acetate. Comparisons between the 2 groups demon-
strated that time-averaged concentrations (weeks 1–8) of
serum phosphorus and Ca × P product were significantly
lower in calcium acetate-treated patients (serum phos-
phorus: 1.08 mg/dL difference, P value = 0.0006; Ca × P
product: 6.1 mg2/dL2 difference, P value = 0.022). At each
treatment week, calcium acetate recipients were 20% to
24% more likely to attain goal serum phosphorus [odds
ratio (OR) 2.37; 95% CI 1.28–4.37, P value = 0.0058], and
15% to 20% more likely to attain goal Ca × P product
(OR 2.16; 95% CI, 1.20–3.86, P value = 0.0097).
Time-averaged weekly concentrations of serum cal-
cium were higher in patients receiving calcium acetate
(0.63 mg/dL difference, P value < 0.0001). Transient hy-
percalcemia was observed in 8 of 48 (16.7%) calcium ac-
etate recipients. Each of these 8 patients was treated with
concomitant intravenous vitamin D. Overall, hypercal-
cemia was substantially more likely to occur in patients
receiving calcium acetate (OR 6.1; 95% CI, 2.8–13.3,
P value < 0.0001). Week 8 iPTH levels were not signifi-
cantly different between the 2 treatment groups. Serum
HCO3 levels were significantly lower during treatment
with sevelamer hydrochloride. Figure 4 compares the ef-
ficacy of calcium acetate and sevelamer hydrochloride
with regard to achievement of K/DOQITM recommended
guidelines for serum phosphorus and calcium, Ca × P
product, and iPTH.
METABOLIC ACIDOSIS DURING TREATMENT
WITH SEVELAMER HYDROCHLORIDE
Short- and long-term studies indicate that treatment
with sevelamer hydrochloride causes a significant reduc-
tion in subjects’ serum HCO3 levels compared with pa-
tients treated with calcium-containing phosphate binders
[8, 9]. Sevelamer hydrochloride is a quaternary amine
anion exchange resin that binds monovalent phosphate
in exchange for release of the leaving anion chloride.
This anion exchange resin may also exchange chloride
for any other anion present in the lumen of the gas-
trointestinal tract. In the small intestine, the local con-
centration of HCO3 is in the range of 120 mEq/L, owing
to the alkaline secretions from the pancreas. Thus, con-
centration gradients in the small intestine would favor
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Fig. 1. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease. In the setting of advancing CKD, secondary hyperparathy-
roidism develops as a consequence of phosphate retention and reduced renal production of active vitamin D, resulting in hyperphosphatemia and
hypocalcemia. When the glomerular filtration rate (GFR) falls much below 70 mL/min, renal excretion of phosphate can no longer keep pace with
gastrointestinal absorption, and phosphorus retention occurs. The resulting hyperphosphatemia inhibits the renal 1–alpha-hydroxylase, so that pro-
duction of active 1,25 dihydroxy vitamin D3 by the kidney is reduced. Vitamin D deficiency then leads to hypocalcemia as a consequence of defective
gastrointestinal calcium absorption and skeletal resistance to the calcemic effect of PTH. The serum-ionized calcium is the most important factor
regulating PTH secretion. The effects of calcium on parathyroid cells are mediated by a membrane-bound calcium-sensing receptor (CaR). Low
serum calcium leads to an increase in PTH secretion, an increase in PTH messenger RNA stability, and parathyroid cell proliferation. Calcimimetic
agents such as cinacalcet increase the sensitivity of the CaR to extracellular calcium, thereby inhibiting the release of PTH and lowering PTH levels
within a few hours of administration. In contrast, active vitamin D modulates PTH production in the parathyroid by binding to the cytoplasmic
vitamin D receptor (VDR). The vitamin D-VDR complex binds to the PTH promoter and inhibits the transcription of PTH mRNA. Thus, vitamin
D deficiency will lead to increased production of PTH message. A chronic decrease in vitamin D levels also leads to parathyroid cell proliferation
and gland hyperplasia. Treatment with vitamin D sterols decreases transcription of the PTH gene, and reduces hormone synthesis and release over
a period of hours to days. There also appears to be a direct effect of phosphate in regulating PTH production by the parathyroid. Although the
sensing mechanism has not yet been characterized, hyperphosphatemia has a direct effect on the parathyroid to increase PTH secretion, increase
PTH messenger RNA stability, and to cause parathyroid cell proliferation. The pathophysiology mechanisms that underlie the development of
hyperphosphatemia and secondary hyperparathyroidism in CKD provide the clinical rationale for treatment strategies that include maintenance of
normal serum phosphorus levels (dietary phosphorus restriction, dietary phosphate binders, and short daily hemodialysis), maintenance of normal
serum calcium (reduced dialysate calcium levels and judicious use of vitamin D analogues), and suppression of PTH secretion (phosphorus control,
maintenance of normocalcemia, and treatment with vitamin D analogues and/or calcimimetic agents, such as cinacalcet).
exchange of chloride for bicarbonate with loss of car-
bonated sevelamer in the stool. The ongoing gastroin-
testinal loss of HCO3 in excess of chloride would lead to
acid loading and metabolic acidosis through a mechanism
akin to chronic diarrhea. Sevelamer hydrochloride can
also exchange chloride for bile acid, and thereby func-
tion to lower serum cholesterol by acting as a bile acid
sequestrant similar to cholestyramine. In the large in-
testine, where sevelamer hydrochloride reaches its final
equilibrium with intestinal fluids before expulsion from
the body, phosphate, HCO3, and bile acid anions repre-
sent minor luminal constituents. The predominant anions
in the colon are short-chain fatty acid anions (SCFAA)
such as acetate, propionate, and n-butyrate, with total
concentrations of 150 mmol/L, constituting more than
70% of luminal anions [10, 11]. These SCFAA are derived
from bacterial fermentation of food residues (mainly car-
bohydrate), and are HCO3 precursors, normally being
absorbed by the intestinal mucosa and incorporated into
intermediary metabolism. Every mole of SCFAA re-
moved from the body by sevelamer, and replaced by
chloride from the resin, thus represents a loss of a mole
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Fig. 2. Mean (± standard error) serum phosphorus levels at baseline
and weekly during treatment with either calcium acetate or sevelamer
hydrochloride. At baseline, mean serum phosphorus levels were not
significantly different between the 2 groups (P = 0.99). Calcium acetate
reduced mean serum phosphorus below the target level of 5.5 mg/dL by
the third week of treatment, and maintained serum phosphorus below
the target level until week 8. In the sevelamer hydrochloride treat-
ment group, mean serum phosphorus never fell below the target level
throughout the 8-week treatment period. Overall, serum phosphorus
levels were significantly lower during treatment with calcium acetate
than during treatment with sevelamer hydrochloride [1.08 mg/dL dif-
ference in average serum concentration (Cavg) during weeks 1–8, P =
0.0006 by covariate-adjusted regression]. To convert values for phos-
phorus to mmol/L, multiply by 0.32.
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Fig. 3. Mean serum Ca × P product at baseline and weekly during
treatment with either calcium acetate or sevelamer hydrochloride. At
baseline, Ca × P product was not significantly different between the 2
groups (P = 0.91). However, Ca × P product was significantly lower
during treatment with calcium acetate than with sevelamer hydrochlo-
ride (6.1 mg2/dL2 difference in Cavg during weeks 1–8, P = 0.0001 by
covariate-adjusted regression). To convert from units of mg2/dL2 to
mmol2/L2, multiply by 0.08.
of HCO3 from the body and its replacement by chloride,
equivalent to a gain by the body of a mole of hydrochloric
acid. Each of these mechanisms could theoretically lead
to generation of a net dietary acid load during treatment
with sevelamer hydrochloride (Fig. 5). Since sevelamer
hydrochloride contains 17% chloride, complete exchange
of chloride for phosphate, HCO3, bile acid, or SSFAA
would lead to a potential net acid load of approximately
4 mEq for each 800-mg sevelamer hydrochloride tablet.
Dietary acid loading during treatment with sevelamer hy-
drochloride has been confirmed in an animal model [12].
Normal rats fed a diet containing sevelamer hydrochlo-
ride develop a significant decrease in urine pH and a
significant increase in urinary ammonium excretion as
measured by an ion-specific electrode. Acidemia should
clearly be avoided in patients with chronic renal failure,
since it has 2 major systemic consequences. Metabolic aci-
dosis has several effects on bone, causing physiochemical
dissolution of bone and cell-mediated bone resorption by
inhibition of osteoblast function and stimulation of osteo-
clast function [13–15]. Chronic metabolic acidosis also
induces a net negative nitrogen and total body protein
balance, which improves following HCO3 supplementa-
tion [16, 17]. These data suggest that metabolic acidosis is
both catabolic and antianabolic. These considerations un-
derscore the urgent need for further studies of acid-base
balance during long-term treatment with sevelamer hy-
drochloride. Given the detrimental effects of metabolic
acidosis on nitrogen balance and bone, the K/DOQITM
guidelines recommend maintaining serum total carbon
dioxide greater than 22 mmol/L [3, 18].
ROLE OF CALCIUM-CONTAINING PHOSPHATE
BINDERS IN PROGRESSION OF
CARDIOVASCULAR CALCIFICATION
Vascular calcification is an important issue in dialysis
patients because it is associated with increased risk of
cardiovascular mortality. However, the underlying causes
of excessive cardiovascular calcification in patients with
advanced CKD are incompletely understood, and are
the subject of intense study [19]. Cardiovascular cal-
cification is most likely a multifactorial process with
numerous potential pathogenic factors, including hy-
perparathyroidism, phosphate loading with hyperphos-
phatemia, hypertension, abnormal glucose metabolism,
abnormalities in lipid metabolism, treatment with vita-
min D analogues and, possibly, deficiencies of kidney-
derived inhibitors of vascular calcification, such as bone
morphogenic protein (Fig. 6) [20]. Thus, it may be overly
simplistic to implicate oral calcium loading from CBPB as
the single most important pathogenic factor in the devel-
opment of cardiovascular calcification in dialysis patients.
Data from observational studies suggest that coronary
artery calcium scores and large-vessel calcification cor-
relate with the prescribed daily dose of CBPB [21, 22].
The Treat-to-Goal study demonstrated that maintenance
dialysis patients treated with sevelamer hydrochlo-
ride have slower progression of coronary and aortic
calcification than patients treated with calcium-
containing phosphate binders [9]. In a more recent post
hoc analysis of Treat-to-Goal study results, Chertow et al
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Fig. 4. Efficacy end points achieved during treatment with calcium acetate (open bars) or sevelamer hydrochloride (closed bars) in the CARE
study. ∗P < 0.05 for calcium acetate vs. sevelamer hydrochloride.
concluded that oral calcium loading resulting from
treatment with CBPB is the key factor associated with
progressive coronary artery and aortic calcification in
dialysis patients [23]. Although the authors conclude
that their findings were most likely due to excess calcium
loading during treatment with CBPB, the design of the
study makes it virtually impossible to test the validity
of this hypothesis. Unfortunately, the study was not
designed such that non–phosphate-binder exposure to
calcium was kept similar between the calcium-based
binder and sevelamer hydrochloride treatment groups.
Instead, supplemental (nonbinder) sources of calcium
were provided to the sevelamer hydrochloride-treated
patients in at least 3 forms: (1) the study design allowed
for the use of calcium carbonate supplements at night
on an empty stomach to treat hypocalcemia in the
sevelamer hydrochloride treatment group; (2) the
dialysate calcium concentration was adjusted during the
study in order to maintain normal serum calcium levels;
(3) sevelamer hydrochloride-treated patients received
larger doses of vitamin D analogues, which might be
expected to enhance gastrointestinal absorption of
dietary calcium. These observations suggest that some
factor other than simple oral calcium loading from the
use of CBPB may be responsible for the finding that
sevelamer hydrochloride-treated patients have slower
progression of cardiovascular calcification. Moreover,
given these deficiencies in study design, it was virtually
impossible for the Treat-to-Goal study investigators to
conclude from any type of post hoc analysis that their
finding of a slower rate of progression in the sevelamer
hydrochloride treatment group was due to reduced
calcium loading.
The failure to achieve equivalent control of LDL and
total cholesterol is another critical issue with regard
to interpretation of the Treat-to-Goal study results. In
comparison with CBPB-treated patients, because seve-
lamer hydrochloride is a bile acid sequestrant, sevelamer
hydrochloride-treated patients had significantly lower
levels of total cholesterol (182 ± 49 mg/dL vs. 141 ±
28 mg/dL; P value < 0.0001) and LDL cholesterol (103 ±
43 mg/dL vs. 65 ± 21 mg/dL; P value < 0.0001) [9]. Be-
cause LDL levels have been shown to play an impor-
tant role in progression of coronary artery calcification
in the general population, the Treat-to-Goal investiga-
tors should have controlled the LDL level in the 2 treat-
ment groups to similar levels. In this regard, lowering
LDL cholesterol with hydroxy-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitor therapy has been re-
ported to ameliorate or even reverse coronary artery cal-
cification in at least 2 studies [24, 25], 1 coauthored by Dr.
Raggi, a senior author of the Treat-to-Goal study [24].
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Fig. 5. Potential mechanisms of acid loading during treatment with sevelamer hydrochloride. Sevelamer hydrochloride is a quaternary amine anion
exchange resin. It is a nonabsorbed polymer chain with covalently linked amino groups, and 40% of these amino groups consist of amine hydrochlo-
ride. Overall, sevelamer hydrochloride contains 17% chloride by weight. The proposed phosphate-binding model for sevelamer hydrochloride is
shown. The quaternary amine resin acts as an anion exchanger whereby monovalent phosphate is bound (via ionic and hydrogen bonding) in
exchange for release of the anion chloride. In this model, 1 molecule of hydrochloric acid is liberated for each molecule of phosphate bound in the
gut. Sevelamer hydrochloride may also exchange chloride for any other anion available in the gastrointestinal tract. In the small intestine, the local
concentration of HCO3 exceeds 100 mEq/L to 120 mEq/L due to alkaline secretion from the pancreas, such that the chemical gradient would favor
binding of HCO3 in exchange for chloride. The elimination of carbonated sevelamer hydrochloride in the stool would result in gastrointestinal loss
of HCO3 in excess of chloride loss, thereby leading to metabolic acidosis via a mechanism similar to that which occurs in the setting of chronic
diarrhea. Sevelamer also functions as a bile acid sequestrant. Binding of a bile acid anion in exchange for chloride leads to net production of hydrogen
chloride. In the large intestine, where sevelamer hydrochloride reaches its final equilibrium with intestinal fluids before expulsion from the body, the
predominant anions in the colon are SCFAA, such as acetate, propionate, and n-butyrate, with total concentrations exceeding 150 mmol/L. These
SCFAA are derived from bacterial fermentation of food residues (mainly carbohydrate), and are HCO3 precursors, normally being absorbed by
the intestinal mucosa and incorporated into intermediary metabolism. Every mole of SCFAA removed from the body by sevelamer hydrochloride
and replaced by chloride from the resin, thus, represents a loss of a mole of HCO3 from the body and its replacement by chloride, equivalent to a
gain by the body of a mole of hydrochloric acid. Thus, binding of phosphate, bicarbonate, bile acid anion, and SCFAA could theoretically lead to
generation of a net dietary acid load and metabolic acidosis during treatment with sevelamer hydrochloride.
Preliminary results of a recent study from Japan demon-
strate that progression of aortic calcification in dialysis
patients was significantly retarded during treatment with
colestimide (a bile acid sequestrant similar to sevelamer
hydrochloride) in combination with atorvastatin com-
pared with the progression rate during the observation
period before lipid-lowering therapy was instituted [26].
The authors speculate that the decrease in aortic calcifica-
tion resulted from control of serum phosphorus and LDL
cholesterol levels. Thus, available information suggests
that the dramatic reduction of LDL cholesterol is a very
compelling potential explanation for the reduced rate of
cardiovascular calcification in sevelamer hydrochloride-
treated dialysis patients.
The critically important issue of increased cardiovas-
cular calcification and mortality in dialysis patients can
only be addressed by well-designed studies that control
for not only the type of phosphate binder but also for
the myriad potential risk factors associated with vascular
calcification. Until such studies are available, it is pre-
mature to abandon calcium-based phosphate binders in
favor of sevelamer hydrochloride because the latter is less
efficacious for control of serum phosphorus and Ca × P
product, and considerably more expensive.
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Fig. 6. Potential pathophysiologic factors leading to excess cardiovascular calcification in patients with ESRD. The exact mechanism of accelerated
atherosclerosis and cardiovascular calcification in chronic kidney disease is unknown, but it is likely a multifactorial process. Traditional risk factors
include age, hypertension, hyperlipidemia, increased homocysteine levels, glucose intolerance with hyperinsulinemia, smoking, and positive family
history. The patient with CKD also has numerous kidney disease-specific risk factors for atherosclerosis and cardiovascular calcification, including
abnormalities of calcium and phosphorus metabolism with secondary hyperparathyroidism, oxidative stress, chronic inflammation, and endothelial
dysfunction.
PROJECTED COSTS FOR PHOSPHATE BINDER
TREATMENT
Projected daily and annual costs based on The Red
Book wholesale prices indicate that calcium acetate
therapy is significantly more economical than sevelamer
hydrochloride therapy. Based on week 8 doses in the
CARE study and per-pill prices of calcium acetate and
sevelamer hydrochloride at $0.15 and $0.64, respectively,
daily per-patient costs for calcium acetate and sevelamer
hydrochloride are estimated at $1.64 and $11.40, respec-
tively. The projected annual per-patient cost of binder
therapy is substantially less with calcium acetate ($600
vs. $ 4100 for sevelamer hydrochloride). Thus, if seve-
lamer hydrochloride were to be universally adopted as
the first-line phosphate binder, the cost for treatment
of the roughly 300,000 dialysis patients in the United
States would increase by more than $1 billion per year.
The lipid-lowering effect of sevelamer hydrochloride may
have a beneficial role in slowing the progression of car-
diovascular calcification in dialysis patients [9]. However,
cost-benefit analysis reveals that combined treatment
with an HMG-CoA reductase inhibitor and calcium-
containing phosphate binders would be a far more
cost-effective alternative. Given the superior efficacy of
calcium acetate for control of serum phosphorus and Ca
× P product, it appears to be the more cost-effective
choice as first-line treatment for hyperphosphatemia in
patients with ESRD on maintenance dialysis [27]. Nev-
ertheless, in the occasional patient who develops per-
sistent hypercalcemia during calcium acetate treatment,
despite appropriate reduction in vitamin D dosage, it may
be prudent to reduce the dose of calcium acetate and
add a non–calcium-containing binder, such as sevelamer
hydrochloride.
CONCLUSION
The CARE study demonstrates that patients with
CKD on maintenance hemodialysis are more effectively
treated with calcium acetate than with sevelamer hy-
drochloride, and more frequently achieve the K/DOQITM
treatment goals for serum phosphorus, Ca × P product,
and HCO3. The pathophysiology of excess cardiovascu-
lar calcification in patients with CKD on maintenance
dialysis is multifactorial, and it is overly simplistic to im-
plicate calcium loading from calcium-based phosphate
binders as the predominant factor leading to vascular cal-
cification. Based on available evidence, it is premature to
abandon efficacious and relatively inexpensive calcium-
based phosphate binder therapy in favor of sevelamer
hydrochloride, which is a less effective phosphate binder
and considerably more expensive. Cost-benefit analysis
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clearly favors calcium acetate as the first-line therapy of
choice for treatment of hyperphosphatemia in dialysis
patients.
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